While both drugs belong to the GLP-1 receptor agonist class, Mounjaro has a dual mechanism (GIP and GLP-1), which clinical ...

Beyond current successes, Eli Lilly is innovating with a potential game-changing oral GLP-1, orforglipron. Read why I ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

U.S. pharma companies should pay rather more of their corporate income tax in the U.S.—and start producing more of their best drugs in the U.S. as well.

Shares of Hims & Hers Health plunged by more than 30% after Danish weight-control drug maker Novo Nordisk abruptly pulled out of a partnership with the telehealth firm on the distribution of Wegovy.

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...

CHICAGO -- Semaglutide (Ozempic) reduced glucose levels and weight among patients with type 1 diabetes and obesity, a ...

Historic changes are afoot for pharma as China gains ground on U.S. production. The pharma industry is projected to see ...

CHICAGO -- An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in ...

BrightGene Pharmaceutical has scored an early win in its push to topple the big beasts of the GLP-1 field. | BrightGene ...

The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo ...

Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination ...